What is the LKKTETQ sequence?

LKKTETQ is the seven-amino acid actin-binding motif at residues 17–23 of Thymosin Beta-4, forming the core of the WH2 (Wiskott-Aldrich syndrome protein Homology 2) domain. It makes specific contacts with the barbed (+) end cleft of G-actin between subdomains 1 and 3, sterically blocking filament elongation. This sequence is the pharmacophore responsible for G-actin sequestration — synthetic peptides containing only LKKTETQ retain approximately 40% of full Tβ4 biological activity in cell-migration assays. Mutation of the conserved leucine-17 or lysine-18 residues abolishes actin-binding capacity entirely.

How is TB-500 different from BPC-157?

TB-500 and BPC-157 have no mechanistic receptor overlap. BPC-157 (15 AA from human gastric juice) acts via extracellular pathways: non-canonical VEGFR2 internalisation independent of VEGF, FAK-paxillin phosphorylation at Tyr397, and bidirectional NO system modulation. TB-500 acts intracellularly: G-actin sequestration via the WH2 domain, ILK/Akt gene expression upregulation, and HIF-1α stabilisation for normoxic angiogenesis. These complementary mechanisms — cytoskeletal mobility (TB-500) vs growth factor receptor and NO signalling (BPC-157) — explain why they are frequently studied in combination as the 'Wolverine stack' in repair research models.

Is TB-500 the same as Thymosin Beta-4?

Not exactly. Thymosin Beta-4 (Tβ4) is the full 43-amino acid, 4.96 kDa natural protein. TB-500 is typically a synthetic 17-amino acid fragment preserving the LKKTETQ WH2 actin-binding domain. The fragment retains G-actin sequestration activity but lacks the C-terminal region that enables full Tβ4's two-ended actin cap, making it a weaker sequesterer. Registered clinical programs (RGN-259 ophthalmic) used full Tβ4, not the TB-500 fragment. Commercial TB-500 preparations vary — some contain only the LKKTETQ heptapeptide, others a longer 17-mer fragment.

Does TB-500 have any human trial data?

Full Tβ4 has Phase 2 clinical data for corneal and wound healing (RGN-259 ophthalmic solution by RegeneRx). Injectable TB-500 (the 17-mer or 7-mer fragment) has no completed human clinical trials for musculoskeletal repair as of 2026. TB-500 is on the WADA Prohibited List (S2 peptide hormones). Titan supplies TB-500 for laboratory and research use only — the existing evidence supports mechanistic investigation in preclinical models, not therapeutic use.

TB-500 mechanism · G-actin sequestration · LKKTETQ · WH2 domain · research use only

How Does TB-500 Work? The Actin Sequestration Mechanism Behind the Research

TB-500 is a synthetic research peptide corresponding to the actin-binding region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein found at high concentrations in platelets and virtually all nucleated mammalian cells. The core mechanistic function of TB-500 is G-actin sequestration: its WH2 (Wiskott-Aldrich syndrome protein Homology 2) domain binds monomeric actin (G-actin) in a 1:1 complex, maintaining a large cytoplasmic reservoir of polymerization-ready actin monomers that cells can rapidly deploy for directed filament growth during migration and tissue repair. This is a mechanistically distinct pathway from BPC-157's VEGFR2-FAK-paxillin-eNOS signalling cascade — the two compounds operate through different molecular machinery on the same cytoskeletal and vascular repair processes. This page explains the G-actin sequestration mechanism, the ILK/Akt survival axis, and the angiogenic pathway with the primary cited data. All information is general educational context about a research compound. Titan Peptide Lab supplies TB-500 for laboratory and research use only — not for human use, not as a drug or therapeutic product, not as medical advice.

TB-500 vial — $89.99 (RUO)BPC-157 + TB-500 Wolverine Stack

What TB-500 is and what it is not

TB-500 is a synthetic research peptide built around the LKKTETQ actin-binding motif of Thymosin Beta-4 (Tβ4). The commercial preparation typically corresponds to a 17-amino acid fragment of Tβ4 preserving the central WH2 domain, though some vendors use the full LKKTETQ heptapeptide alone. This is mechanistically important: full Tβ4 is a 43-amino acid, 4.96 kDa protein with N-terminal and C-terminal regions that contribute additional functional domains beyond G-actin sequestration — including the ILK/Akt cardiac survival signalling axis discovered by Bock-Marquette et al. 2004 (Nature, mouse cardiac ischemia model). The LKKTETQ fragment retains the primary actin-binding function but binds G-actin with somewhat lower affinity than the intact protein because the two-ended cap that full Tβ4 places on the actin monomer (barbed end + pointed end contacts) requires the flanking C-terminal region. TB-500 is not the same compound as the full-length Tβ4 used in registered clinical trials (RGN-259, an ophthalmic preparation for dry eye/corneal healing studied by RegeneRx). When research citing full Tβ4 is used to interpret TB-500 data, this structural distinction should be noted.

TB-500 dosage reference →

Primary mechanism: G-actin sequestration via WH2/LKKTETQ

The WH2 domain of TB-500 occupies the hydrophobic cleft between subdomains 1 and 3 of monomeric G-actin, sterically blocking the barbed (+) end that would otherwise initiate filament elongation. The dissociation constant of the TB-500:G-actin complex is approximately 0.5–0.7 µM — tight enough to maintain a large sequestered pool, but loose enough to permit rapid release when nucleation factors (Arp2/3 complex, formins) compete for available monomer supply. In resting cells, approximately 50% of all actin exists as free G-actin monomers, and much of this pool is TB-500/Tβ4-bound. When a cell receives a migratory or repair signal — growth factor gradient, wound edge, cytokine — profilin and Arp2/3 complex compete with TB-500 for G-actin monomers, displacing the peptide and allowing directed F-actin assembly at the leading edge. TB-500 therefore acts as a regulated actin buffer rather than a simple inhibitor: it stores monomers and releases them on demand. In cells overexpressing Tβ4, this buffer effect produces a 3-fold increase in lamellipodia formation and a 40% increase in cell migration velocity in scratch-wound assays. Malinda et al. 1999 (J Invest Dermatol 113:364-368, PMID 10469335) showed the LKKTET peptide alone produced 42% → 61% reepithelialization in mouse wound models, confirming the actin-binding domain as the functional core.

Peptides for recovery research hub →

ILK/Akt survival signalling: the second mechanistic axis

Independently of G-actin sequestration, Thymosin Beta-4 activates integrin-linked kinase (ILK) — a serine/threonine kinase at the integrin-cytoskeleton interface that is part of the PI3K/Akt cell survival pathway. ILK does not bind Tβ4 directly; instead, Tβ4 upregulates ILK gene expression, increasing ILK protein levels that then phosphorylate Akt at Ser473 and GSK-3β at Ser9 — downstream events that reduce apoptosis and promote cell survival in damaged tissue. Bock-Marquette et al. 2004 (Nature) demonstrated this pathway specifically in cardiac tissue: Tβ4 treatment in a mouse cardiac ischemia model activated ILK → Akt → GSK-3β → epicardial progenitor cell migration and cardiomyocyte survival post-injury. This axis does not require the WH2 actin-binding domain and is mechanistically distinct from G-actin sequestration — suggesting Tβ4 has modular functional domains with different downstream targets. ILK activation also drives VEGF upregulation via the transcription factor MRTF-A, linking the survival axis to the angiogenic pathway below.

BPC-157 vs TB-500 comparison →

Angiogenic pathway: HIF-1α stabilisation → VEGF

A third mechanistic axis links TB-500 directly to angiogenesis through hypoxia-inducible factor (HIF) signalling. Under normal (normoxic) conditions, HIF-1α — the master transcriptional regulator of the cellular hypoxic response and the primary driver of VEGF expression — is rapidly degraded via prolyl hydroxylase-mediated ubiquitination. Ock et al. 2012 demonstrated that Thymosin Beta-4 stabilises HIF-1α protein in an oxygen-independent manner, allowing VEGF transcription under normoxic conditions. This normoxic HIF-1α stabilisation means TB-500 can activate angiogenic programmes without requiring hypoxic conditions — a property relevant to in vitro research systems operating at atmospheric O2. The combined angiogenic profile (endothelial cell G-actin sequestration → migration + VEGF upregulation via ILK-MRTF-A + HIF-1α stabilisation) represents three mechanistic contributions to new blood vessel formation rather than the single-pathway approach of VEGFR2-targeted compounds.

Peptides for inflammation research →

How TB-500 differs mechanistically from BPC-157

BPC-157 and TB-500 are frequently studied together because they have complementary mechanisms addressing the same downstream biological outcomes — cell migration, angiogenesis, tissue repair — through entirely different molecular routes. BPC-157 (15 AA, derived from human gastric juice) acts through extracellular and membrane-associated pathways: non-canonical VEGFR2 internalisation (independent of VEGF ligand), focal adhesion kinase (FAK)-paxillin phosphorylation at Tyr397, and bidirectional NO system modulation. TB-500 acts intracellularly: G-actin sequestration via the WH2 domain (cytoskeletal mechanism), ILK/Akt gene expression upregulation (survival mechanism), and HIF-1α stabilisation (angiogenic mechanism). There is no meaningful receptor-binding overlap between the two compounds. Their complementary rather than redundant mechanisms are the mechanistic rationale for the BPC-157 + TB-500 research pairing. Neither compound has a completed human RCT as the 17-mer fragment (TB-500) or the 15-mer peptide (BPC-157) for musculoskeletal repair.

How does BPC-157 work? →

What the mechanism data doesn't establish

The mechanistic and preclinical evidence for Thymosin Beta-4 is well-documented across cell biology, wound healing, cardiac, and corneal research. Registered clinical trials (RGN-259 dry eye, epidermolysis bullosa) used full-length Tβ4 in an ophthalmic formulation — NOT the injectable 17-mer fragment sold as TB-500. The specific TB-500 fragment is more weakly studied in isolation, and its reduced G-actin binding affinity vs full Tβ4 (only the barbed-end contact, not the two-ended cap) means extrapolation from full Tβ4 data to TB-500 must note the structural difference. TB-500 is also on the WADA Prohibited List (S2 peptide hormones). No human RCT of injectable TB-500/Tβ4 fragment for musculoskeletal repair has been completed as of 2026. Titan supplies TB-500 for laboratory and research use only; the existing evidence supports preclinical mechanistic investigation, not any approved therapeutic use.

TB-500 safety and tolerability data →

Three mechanistic axes — sourced and plain

TB-500's mechanistic pathways: G-actin sequestration, ILK/Akt survival, and HIF-1α angiogenesis.

Each row covers one mechanism, the key source, and the caveat that applies. G-actin sequestration is the primary, best-characterised axis; ILK/Akt and HIF-1α are secondary but mechanistically independent.

G-actin sequestration via WH2/LKKTETQ (primary): WH2 domain binds G-actin barbed end, Kd ~0.5–0.7 µM, 1:1 ratio. Maintains releasable actin monomer buffer → 3× lamellipodia formation, +40% migration velocity on migratory signal. Malinda et al. 1999 PMID 10469335: LKKTET → 42→61% reepithelialization (mouse wound model). The TB-500 fragment binds weaker than full Tβ4 (lacks C-terminal contact).
ILK/Akt survival signalling (secondary): Tβ4 upregulates ILK gene expression → ILK phosphorylates Akt (Ser473) + GSK-3β (Ser9) → anti-apoptotic cell survival signal. Bock-Marquette et al. 2004 Nature: Tβ4 → ILK → cardiac progenitor migration + cardiomyocyte survival post-ischemia in mice. Distinct from G-actin sequestration — does not require the WH2 domain.
HIF-1α stabilisation → VEGF (angiogenic): Tβ4 stabilises HIF-1α in normoxic conditions (Ock et al. 2012) → VEGF transcription without hypoxia requirement. ILK-MRTF-A axis also drives VEGF upregulation independently. Combined: three routes to new vessel formation vs BPC-157's single VEGFR2-internalisation axis.
NF-κB suppression → anti-inflammatory resolution: Tβ4 upregulates IκBα, an NF-κB inhibitor, reducing pro-inflammatory transcription of IL-6 and TNF-α. Anti-inflammatory mechanism documented in cardiac and wound models. Complements the actin-migration axis (cells must resolve inflammation to complete repair).
TB-500 vs full Tβ4: the fragment caveat: Commercial TB-500 = 17-mer or 7-mer LKKTETQ fragment of full 43-AA Tβ4. Fragment retains G-actin binding (primary function) but lacks the two-ended barbed+pointed-end cap of intact Tβ4, reducing binding affinity. Clinical data (RGN-259 corneal trials) used full Tβ4, not the fragment — extrapolation must note the structural difference.
Distinction from BPC-157: BPC-157: extracellular VEGFR2 internalisation (VEGF-independent) + FAK-paxillin Tyr397 phosphorylation + NO system bidirectional modulation. TB-500: intracellular G-actin sequestration (cytoskeletal) + ILK/Akt gene upregulation + HIF-1α stabilisation. No receptor overlap. Mechanistic complement — explains the BPC-157 + TB-500 research pairing.

Questions researchers ask

Before you order.

How does TB-500 work?: TB-500 works primarily through G-actin sequestration: its LKKTETQ actin-binding domain (WH2 motif) binds monomeric G-actin in a 1:1 complex at micromolar affinity (Kd ~0.5–0.7 µM), maintaining a large releasable pool of polymerization-ready actin monomers inside cells. When cells receive repair or migratory signals, they draw from this reservoir to rapidly form F-actin filaments at the leading edge — enabling 3× greater lamellipodia formation and 40% faster migration velocity vs controls. Simultaneously, Thymosin Beta-4 activates integrin-linked kinase (ILK) → Akt → cell survival signalling (Bock-Marquette 2004, Nature) and stabilises HIF-1α for normoxic VEGF-driven angiogenesis.
What is the LKKTETQ sequence?: LKKTETQ is the seven-amino acid actin-binding motif at residues 17–23 of Thymosin Beta-4, forming the core of the WH2 (Wiskott-Aldrich syndrome protein Homology 2) domain. It makes specific contacts with the barbed (+) end cleft of G-actin between subdomains 1 and 3, sterically blocking filament elongation. This sequence is the pharmacophore responsible for G-actin sequestration — synthetic peptides containing only LKKTETQ retain approximately 40% of full Tβ4 biological activity in cell-migration assays. Mutation of the conserved leucine-17 or lysine-18 residues abolishes actin-binding capacity entirely.
How is TB-500 different from BPC-157?: TB-500 and BPC-157 have no mechanistic receptor overlap. BPC-157 (15 AA from human gastric juice) acts via extracellular pathways: non-canonical VEGFR2 internalisation independent of VEGF, FAK-paxillin phosphorylation at Tyr397, and bidirectional NO system modulation. TB-500 acts intracellularly: G-actin sequestration via the WH2 domain, ILK/Akt gene expression upregulation, and HIF-1α stabilisation for normoxic angiogenesis. These complementary mechanisms — cytoskeletal mobility (TB-500) vs growth factor receptor and NO signalling (BPC-157) — explain why they are frequently studied in combination as the 'Wolverine stack' in repair research models.
Is TB-500 the same as Thymosin Beta-4?: Not exactly. Thymosin Beta-4 (Tβ4) is the full 43-amino acid, 4.96 kDa natural protein. TB-500 is typically a synthetic 17-amino acid fragment preserving the LKKTETQ WH2 actin-binding domain. The fragment retains G-actin sequestration activity but lacks the C-terminal region that enables full Tβ4's two-ended actin cap, making it a weaker sequesterer. Registered clinical programs (RGN-259 ophthalmic) used full Tβ4, not the TB-500 fragment. Commercial TB-500 preparations vary — some contain only the LKKTETQ heptapeptide, others a longer 17-mer fragment.
Does TB-500 have any human trial data?: Full Tβ4 has Phase 2 clinical data for corneal and wound healing (RGN-259 ophthalmic solution by RegeneRx). Injectable TB-500 (the 17-mer or 7-mer fragment) has no completed human clinical trials for musculoskeletal repair as of 2026. TB-500 is on the WADA Prohibited List (S2 peptide hormones). Titan supplies TB-500 for laboratory and research use only — the existing evidence supports mechanistic investigation in preclinical models, not therapeutic use.